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Abstract: 
Alzheimer’s disease (AD) is the most widespread neurodegenerative disorder, affecting 
approximately 20 million people worldwide.  AD pathology is primarily characterized by the 
formation of extracellular amyloid plaques resulting from the aggregation of insoluble amyloid-
β1-42 (Aβ), and neurofibrillary tangles (NFT’s) resulting from intracellular aggregation of 
hyperphosphorylated tau protein.  The current FDA-approved AD treatments do not stop or 
reverse neurodegeneration, but only treat the symptoms by increasing acetylcholine 
neurotransmitter.  Our laboratory is attempting to provide an additional therapeutic approach by 
using neurotrophic factors to block apoptosis or to restore neurons.  We previously demonstrated 
that, in an in vitro model for AD, hEPN-1 neurotrophic factor mimetics can block synthetic Aβ-
induced neuronal cell death when added to cultures, presumably by blocking caspase activation.  
In this thesis, we extended these findings to study the effect of Aβ and hEPN-1 on tau 
hyperphosphorylation (as measured by immunoblots with phospho-specific antibodies) and 
nuclear DNA fragmentation (as measured by TUNEL staining), both in vitro and in vivo in AD 
transgenic mice.  We found that Aβ induces the hyperphosphorylation of tau in both mouse N2a 
and human SHSY neuronal cells, and that hEPN-1 may lower this phosphorylation in N2a cells.  
Furthermore, we discovered that hEPN-1 can reduce nuclear DNA fragmentation when added 
both simultaneously to Aβ and 3 and 6 hours post Aβ addition.  Finally, in vivo hEPN-1 may 
lower both tau hyperphosphorylation and caspase-7 related protein (C7RP) in AD transgenic 
(Tg) mice.  The overall results validate our in vitro AD model, show the efficacy of hEPN-1 at 
blocking Aβ-induced DNA fragmentation even when added post-insult, and show that hEPN-1 
may work in an AD mouse model.  However, more studies must be conducted to confirm these 
findings.  
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Introduction: 
 
 Alzheimer’s disease (AD), characterized by senile plaques and neurofibrillary tangles 
formed by deposits and aggregations of abnormally processed proteins, is currently the most 
widespread neurodegenerative disorder (Goedert and Spillantini, 2006).  In fact, the disease 
affects approximately 20 million individuals worldwide (Goedert and Spillantini, 2006), more 
than 5 million of whom are Americans (Alzheimer’s Foundation of America, 2007).  
Unfortunately, these numbers are predicted to increase drastically, with the number of affected 
Americans projected to be about 16 million by the year 2050 (Alzheimer’s Foundation of 
America, 2007).  AD is a progressive disease, meaning that symptoms become worse as an 
affected person ages (Alzheimer’s Association, 2007).  Signs of AD generally become apparent 
when someone is over the age of 65, with about 1 in 10 individuals over 65 having the disease 
(Alzheimer’s Foundation of America, 2007).  Conversely, early onset AD can affect individuals 
before they are 65, which generally occurs if there is a family history of the disease (Fisher 
Center for Alzheimer’s Research Foundation, 2007).  Since AD is a dementia-causing disease, 
the most common symptoms include memory loss, loss of motor function, and loss of 
communication skills.  Some of the lesser known symptoms include depression, and changes in 
behavior and personality (Alzheimer’s Foundation of America, 2007).  
At present, AD neuronal degeneration is irreversible, and no cure exists.  FDA-approved 
drugs for treating the symptoms are on the market, but they only act to decrease 
acetylcholinesterase activity to increase the concentration of acetylcholine neurotransmitter at 
synapses, or to block NMDA-mediated excitatory signalling to slightly delay disease progression 
(Roberson and Mucke, 2006; Alzheimer’s Foundation of America, 2007).  The ill success of 
these drugs can in part be attributed to the fact that the full mechanism of the disease process is 
9 
unknown.  Although a few drugs that decrease the activity of gamma secretase to diminish the 
formation of Aβ are currently in human clinical trials, supplementary approaches need to be 
devised to block apoptosis and to restore neurons.  If any successful treatments are to be 
developed, knowing more completely the mechanism of disease is of utmost importance.  
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Background 
 
Amyloid Cascade Hypothesis 
Currently, the complete mechanism of Alzheimer’s disease has not been fully identified.  
However, research has lead to several theories as to what factors play key roles in AD 
pathogenesis.  For decades, scientists have known that the two major hallmarks of AD in the 
brain are extracellular senile plaques and intracellular neurofibrillary tangles (NFTs), composed 
of aggregates of Aβ or hyperphosphorylated tau, respectively (Figure 1).  Aβ is a 42-amino acid 
protein formed from the abnormal processing the amyloid precursor protein (APP) and is 
neurotoxic.  Tau is a microtubule stabilizing protein important for axon structure and function. 
The extent of senile plaque deposition does not always correlate with the severity of the disease, 
so more recent AD theories argue that earlier steps in plaque formation, such as Aβ formation 
and early aggregation, are far more critical to the observed neurodegeneration.  
 
Figure 1: Images of the Two Main Hallmark Lesions of AD. 
A. Senile plaques caused by aggregations of amyloid-β. B. 
Neurofibrillary tangles caused by aggregations of tau (Figure from 
Armstrong, 2006).  
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The amyloid cascade hypothesis is presently the most comprehensive explanation of AD 
pathogenesis, and the most widely accepted.  This hypothesis incorporates genetic factors that 
can initiate the disease, and includes changes in protein processing that lead to the hallmark 
lesions, and finally neurodegeneration and dementia (Figure 2).  Initiation of AD is thought to be 
caused by the abnormal processing of amyloid precursor protein (APP) on the surface of neurons 
and microglial cells.  When APP is abnormally cut by gamma and beta-secretases, or when the 
APP gene is mutated in early onset AD to facilitate abnormal cutting, a 42 amino acid fragment 
(Aβ1-42) is released.  Aβ can form aggregates, which over time result in higher order structures 
that form senile plaques.  All forms of Aβ appear to be highly neurotoxic, including monomers, 
dimers, trimers, and even senile plaques, but the lower order structures are the most toxic. 
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Figure 2: Diagram of the Amyloid Cascade Hypothesis for AD.   
This hypothesis suggests that AD begins with mutations in specific genes, such as APP and the 
presenilins, or by unknown causes, that leads to the production of amyloidogenic Aβ1-42, via abnormal 
APP processing.  Aβ1-42 (red in the diagram) oligomerizes and is neurotoxic.  Neurotoxic Aβ aggregates 
affect synapses, and eventually damage whole neurons.  Neuronal injury can lead to an upset in ionic 
balance in the brain, leading to cellular oxidative stress, which further damages the neurons.  Formation 
of oligomeric Aβ may also alter proteasome activity, which results in the accumulation of 
hyperphosphorylated, truncated, and misfolded tau.  Further processing of tau results in neurofibrillary 
tangles, which lead to dysfunctional neurons and eventually apoptosis.  As neurons degenerate in the 
diseased brain, the onset of dementia becomes apparent (Figure from Verdile et al., 2004). 
 
Aβ is a protein fragment of either 40 or 42 amino acids, and is generated by the cleavage 
of the 770 amino acid amyloid precursor protein (APP) (Goedert and Spillantini, 2006).  APP is 
a conserved protein across several species, has been implicated in cell-cell adhesion and cell-
matrix adhesion, and may also be involved in neurite outgrowth as well as synaptogenesis 
(Zheng and Koo, 2006).  APP can be cleaved by α, β, and γ-secretase enzymes.  When 
abnormally cleaved sequentially by β-secretase and γ-secretase, Aβ is the resultant fragment 
(Figure 3).  While Aβ can exist as either 40- or 42-amino acids, the 42-amino acid version is 
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more abundant in the plaques of diseased brains (Yuan and Yankner, 2000), suggesting that it 
contributes more to Alzheimer’s disease pathology than the 40-amino acid protein.   
 
 
Figure 3: Schematic of APP Cleavage.   
Full-length APP (green, top bar) is a 770 amino acid transmembrane protein.  The Aβ 
portion of APP is indicated in yellow.  Under AD conditions (right side) β-secretase first 
cleaves APP at the N-terminus of Aβ, followed by cleavage at the C-terminus by γ-
secretase to produce a highly neurotoxic Aβ fragment.  Under non-disease conditions 
(diagram left side), α-secretase cleaves APP in the middle of the Aβ fragment to result in 
non toxic APP fragments (Figure from Goedert and Spillantini, 2006). 
    
The produced Aβ collects extracellularly and forms dimers, trimers, and eventually oligomers 
(Hardy and Selkoe, 2002).  All forms of Aβ are neurotoxic, however the lower order structures 
have been shown to be more neurotoxic than insoluble senile plaques, which may explain why 
plaques do not correlate well with disease severity.  The oligomers have been shown to be the 
most neurotoxic, and have been implicated in the reduction of long-term potentiation in the 
hippocampus (Walsh et al., 2002).  Eventually, aggregations of Aβ in its various forms 
(oligomers, fibrils, etc.) form senile plaques, even after the affected neuron has degenerated.  
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These plaques may also disrupt proper brain function, but a strong correlation between plaques 
and cognitive decline has not been shown. 
 
AD Genetics 
Genetic mutations implicated in initially causing AD occur in the presenilin-1 or -2 genes 
(Sherrington et al., 1995; Levy-Lahad et al., 1995; Goedert and Spillantini, 2006), and in the 
amyloid precursor protein (APP) gene.  Generally, mutations in the presenilin genes or APP are 
responsible for familial AD (FAD) (early-onset), which accounts for only about 5% of reported 
cases (Alonso et al., 2001).  These mutations lead to abnormal APP processing, resulting in an 
increased production of Aβ1-42 (Yuan and Yankner, 2000; Goedert and Spillantini, 2006).  Aβ1-42 
is the more amyloidogenic form of the protein, as compared to Aβ1-40 (Goedert and Spillantini, 
2006), and is also found in greater abundance in amyloid plaques of diseased brains.   
In addition to specific genetic mutations, the presence of the ε4 allele of apolipoprotein E 
(APOE) (Roberson and Mucke, 2006), present in about 15 percent of the U.S. population 
(Christensen et al., 2008), is also associated with AD.  It is unknown how this allele relates to 
AD, but some evidence argues it accelerates Aβ formation, and leads to cytoskeletal 
inconsistencies and impaired mitochondrial function (Roberson and Mucke, 2006). 
 
AD Mechanisms 
Research has shown that extracellular Aβ binds to and activates the receptor for advanced 
glycation end products, or RAGE (Yan et al., 1996) (Figure 4).  RAGE expression is upregulated 
in AD, and this molecule has been shown to act as a moderator for some of the key interactions 
between Aβ and neurons.  RAGE bound to Aβ results in increased cellular oxidative stress (Yan 
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et al., 1996) and eventually leads to apoptosis.  Aβ may also interact with a few other surface 
receptors, including APP itself, and p75 receptors (Yuan and Yankner, 2000) (Figure 4).  Finally, 
Aβ may indirectly activate a tumor necrosis factor receptor (TNF-R) by interacting with 
microglia, which in turn release tumor necrosis factor-α (TNF-α).  TNF-α then triggers the TNF-
R, which stimulates intracellular death signals (Yuan and Yankner, 2000) (Figure 4).   
 
 
 
Figure 4: Schematic of Aβ Interaction with Neuronal Surface Receptors.   
Aβ can interact with several receptors on the surface of neurons, including RAGE, APP, and p75.  It can 
also interact with RAGE on microglial cells, which release TNF-α.  TNF-α triggers the TNF-R receptor.  
Activation of such surface receptors by Aβ can result in an increase of calcium ions and reactive oxygen 
species within the neuron.  It can also result in the stimulation of the caspase pathway, which is a 
mediator for cellular apoptosis.  Other pathways that result in the hyperphosphorylation of tau can also be 
activated as a result of Aβ accumulation (Figure from Yuan and Yankner, 2000). 
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Although Aβ1-42 is highly neurotoxic, the receptor binding domain exists between amino 
acids 25 and 35 (Yankner et al., 1990) (Figure 5).  Thus, Aβ25-35, also known as the Yankner 
peptide since it was first discovered by Bruce A. Yankner, is commonly used to induce 
neurodegeneration under experimental conditions, as it is shorter and cheaper to manufacture 
than full length Aβ.  While other varying lengths of Aβ are also used in experimentation, the 
Yankner peptide is the shortest active portion, so we have chosen the Yankner peptide as an Aβ 
insult for our in vitro AD assays.   
 
Figure 5: Amino Acid Sequences of Aβ and the Yankner Peptide.   
Amino acids 25-35 (shown in red) represent the shortest functional portion of full-length Aβ (adapted 
from Yankner et al., 1990).   
 
Oxidative stress also plays a strong role in AD.  While a mechanism for oxidative stress 
in the AD brain has not been completely explained, studies have shown that AD brains show 
increased amounts of oxidative damage as compared to age-matched controls (Smith et al., 
2000).  Eventually, the diseased brain is unable to produce enough anti-oxidant enzymes, such as 
superoxide dismutase (SOD), catalase (CAT), or glutathione peroxidase (GPX), to defend 
against reactive oxygen and free radicals, which can result in significant cellular damage (Smith 
et al., 2000; Shashoua et al., 2004).   
 
AD and Caspases 
Apoptosis is a highly regulated form of cell death, and operates under a fairly specific 
program.  Apoptosis occurs widely during development to help control the number of new cells 
D A E F R H D S G Y E V H H Q K L V F F A E D V G S N K G A I I G L M V G G V V I A
1 4225 35
Yankner Peptide
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that remain in an organism, and also occurs throughout an organism’s life to help maintain the 
correct number of cells (Fan et al., 2005).  Several events characterize apoptosis, including 
membrane blebbing, decrease in cell volume, chromatin condensation, caspase activation, 
mitochondrial release of cytochrome c, and nuclear DNA fragmentation (Cohen, 1997; 
Sundquist et al., 2006).  The interaction of Aβ with any of the receptors shown in Figure 4 
triggers several intracellular processes that are involved in cellular apoptosis and degeneration. 
One of the major pathways activated in cell death is the caspase pathway, which consists 
of a hierarchy of several caspases being successively activated to eventually lead to cell death.  
Caspases are aspartate-specific cysteine proteases that are normally expressed as inactive 
zymogens, or procaspases (Fan et al. 2005).  However, when the caspase pathway is stimulated, 
procaspases are cleaved at aspartate cleavage sites into the catalytically active form of the 
enzyme (Cohen, 1997; Yuan and Yankner, 2000).  All of the 14 currently known caspases have 
the ability to activate themselves or other caspases (Fan et al. 2005).  Several members of the 
caspase family of proteins have been identified as key players in cellular apoptosis.  These 
include caspases-2, -8, -9, -10, and -12, which act as initiator caspases, and caspases-3, -6, and -
7, which act as effector caspases (Chen and Wang, 2002; Fan et al., 2005) (Figure 6).  Initiator 
caspases respond to stimulation of a surface death ligand (2, 8, and 10) or internal mitochondrial 
or endoplasmic reticulum stress (9 and 12, respectively).  Effector caspases eventually respond to 
the activation of the initiator caspases and/or the release of various proteins into the cytosol, and 
ultimately trigger cellular apoptosis (Fan et al., 2005). 
Since caspase-3 is known to be a key end-stage effector caspase, activated by any of the 
other caspase pathways, it is a good marker candidate for studying apoptosis.  Once procaspase-3 
is cleaved into caspase-3, it interacts with several substrates to produce molecules that lead to 
apoptosis.  While caspase-9 can activate caspase-3, caspase-3 can also activate caspase-9, 
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creating a positive feedback loop of caspase activation, further perpetuating and amplifying 
apoptotic signals within a cell (Fan et al., 2005).  Because caspase-3 is a late-stage apoptotic 
protein, it should be highly expressed and active in dying cells, and should be easily detected.  
Using an in vitro model of AD where a majority of cells are dying and presumably apoptotic, our 
laboratory previously showed that procaspase-3 protein levels are upregulated by Aβ, and its 
activity increases, suggesting that the cells are indeed undergoing apoptosis (Kapoor, 2007).  
 
Figure 6: Diagram of the Caspase Cascade That Leads to Apoptosis.    
A surface death ligand is activated, which in turn activates initiator caspases-8, -10, and -
2 (latter caspase added to diagram).  These, along with mitochondrial stress, can lead to 
the activation of caspase-9.  Endoplasmic reticulum stress can also trigger events that 
result in caspase-12 activation.  Finally, these pathways activate effector caspases-3, -6, 
and -7, which lead to apoptosis (Figure from Fan et al., 2005). 
 
/-2 
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AD and Tau Protein 
One end stage result of Aβ induced pathways involves the hyperphosphorylation of tau 
protein.  This process is thought to begin with an increase in Ca2+ ions within the cell, which can 
trigger the activation of calpains (Figure 4).  Calpains are proteases involved in important 
physiological cellular functions, but when activated by a cellular insult, can become mediators of 
degeneration (Glass et al., 2002).  The activation of calpains can initiate caspases, but can also 
activate cyclin-dependent kinase 5 (cdk5), which is one of several kinases known to 
phosphorylate tau (Maccioni et al., 2001).  Once phosphorylated, tau loses its ability to bind 
microtubules; when too much phosphorylation occurs (hyperphosphorylation), tau tends to 
aggregate and form NFTs, which play a role in the ultimate degeneration of the neuron (Yuan 
and Yankner, 2000) (Figure 4).   
For many years it was thought that the neuronal damage caused by tau was separate and 
distinct from that caused by Aβ, and that isolated processes were involved in the pathology 
triggered by each protein.  In fact, historically AD researchers were often divided in this respect, 
either supporting Aβ or tau, but not both.  However, more recent discoveries suggest that tau and 
Aβ work together to cause the neuronal degeneration seen in AD, and in fact, they are both 
necessary in the degeneration process (Rapoport, 2002; Marx, 2007; Roberson et al., 2007), and 
several studies recently support this hypothesis. 
One such study was conducted by Rapoport et al. (2002).  This group used a mouse 
model to test whether tau was necessary for neurotoxicity induced by Aβ.  Using wild type and 
homozygous tau knockout mice, as well as transgenic mice for human tau generated on a tau null 
background, they used cells taken from the hippocampi of 16-day-old embryos of both 
engineered strains, and compared those to wild type mouse embryos.  When cells from either the 
wild type or transgenic mice (both containing tau) were incubated with Aβ, distinct and severe 
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neurodegeneration was observed.  However, when cells from the tau knockout mice were 
exposed to Aβ, no degeneration was seen.  As a result, they concluded that tau is essential to the 
neurotoxicity that occurs when Aβ is present (Rapoport et al., 2002).  
Another study which supports the hypothesis that both Aβ and tau are necessary for AD 
pathology was conducted by Roberson et al. (2007), using an AD mouse model.  This group 
engineered mice to contain a mutant human APP gene, and also to contain either 0, 1, or 2 copies 
of the endogenous tau allele.  They compared these mice to age-matched mice with 0, 1, or 2 
copies of the tau allele but no human APP.  The researchers found that while the general health 
of all the mice was comparable (i.e. weight, gross motor function, etc.), mice containing the 
human APP gene and 2 tau alleles performed poorly on different types of mazes.  In contrast, 
mice containing the human APP gene and 0 tau alleles performed at levels comparable to control 
mice.  Upon further analysis, it was found that mice containing human APP and 0, 1, or 2 copies 
of tau showed no differences in Aβ plaque area or percentage containing dystrophic neurites 
(Roberson et al., 2007).  Thus, Aβ plaques continue to form even in the absence of tau, but do 
not subsequently affect motor function or memory when no tau alleles are present, suggesting 
that both proteins are required for AD pathology.  Other researchers have discovered that in the 
absence of tau, although Aβ plaques still form, typical neuron loss seen in AD is not observed 
(Lewis et al., 2001).  Thus Aβ deposition appears to be upstream of NFT formation.   
Since the presence of Aβ in the absence of tau induces plaque formation but no neuron 
loss, it is likely that Aβ is deposited before changes in tau occur.  It has been suggested that the 
buildup of Aβ might cause the proteasome to malfunction, thus resulting in abnormal or 
damaged tau not being cleared from the neurons (Oddo et al., 2004).  A dysfunctional 
proteasome could eventually lead to aggregations of abnormal tau that ultimately become NFTs.   
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Additionally, this research supports the amyloid cascade hypothesis, which suggests that 
Aβ oligomers first form plaques that interfere with proper neuronal function, and alter the 
function of kinases, phosphatases, and proteases, leading to abnormal tau processing and 
clearance (Hardy and Selkoe, 2002).  
The normal function of Tau within a healthy neuron is to assemble and stabilize 
microtubules (Rissman et al., 2004; Goedert and Spillantini, 2006), and to mediate the transport 
of materials up and down an axon (Rissman et al., 2004).  It is interesting that in the 
aforementioned studies the researchers were able to knock out tau without lethal effects to the 
mice.  Since tau is not the only microtubule stabilizing protein (others include MAP1A and 
MAP1B), it is possible that these proteins somewhat compensate for the loss of tau, enough to 
allow mice to survive in the absence of tau (Harada et al., 1994).  In a normal human brain, six 
isoforms of tau are present.  These isoforms are produced by alternative splicing of the mRNA 
that codes for the tau protein (Rissman et al., 2004; Goedert and Spillantini, 2006).  They include 
3 isoforms containing 4 microtubule-binding repeats, and 3 isoforms containing 3 microtubule-
binding repeats (all located on the C-terminus).  Additionally, 1 each of the 4 and 3 repeat 
isoforms contains either 2, 1, or 0 N-terminal inserts (Alonso et al., 2001; Goedert and 
Spillantini, 2006) (Figure 7).  
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Figure 7: Diagram of the Six Tau Isoforms Found in the Human Brain.   
Exons (1-13) are shown at the top of the diagram, with the exons that can be alternatively 
spliced shown as crosshatched boxes (exons 2, 3, and 10).  The black boxes indicate the 
microtubule binding repeats.  The nomenclature at the right of the diagram distinguishes 
the isoforms from one another by stating the number of repeats and the number of N 
terminal inserts (i.e. 4R2N = 4 binding repeats + 2 N terminal inserts) (Figure from 
Hasegawa, 2006).   
 
The six tau isoforms have been observed in NFTs in AD, though no marked differences 
have been identified for their proportions in AD versus normal brain (Goedert and Spillantini, 
2006).  One notable difference, however, is that the tau isoforms isolated from an AD brain are 
hyperphosphorylated, whereas the isoforms from a normal brain are not (Alonso et al., 2001).  
 Phosphorylation of a protein usually occurs at specific sites to allow the protein to 
function properly.  It is imperative that phosphorylation and dephosphorylation of a protein occur 
correctly so that a protein can function appropriately.  For example, phosphorylation of tau 
reduces its ability to bind microtubules, whereas dephosphorylation allows tau to bind to and 
stabilize microtubules.  The longest isoform of human tau contains several serine/threonine 
phosphorylation sites (Figure 8).  Approximately 8-10 of these sites are phosphorylated at any 
given time in a normal brain (Goedert, 1999), but in AD phosphorylation and dephosphorylation 
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do not occur correctly and the tau protein can become hyperphosphorylated, which can 
drastically alter its function.  Hyperphosphorylation is when several more phosphate groups than 
normal are added to a protein, usually as a result of overactive kinases or underactive 
phosphatases.  The paired helical filament (PHF) tau from AD brains has revealed 
phosphorylation at greater than 20 different sites at any given time (Goedert, 1999) (Figure 9), 
suggesting that tau is indeed hyperphosphorylated in AD.  Therefore, the hyperphosphorylation 
of tau has been implicated as a key part of the mechanism by which NFT pathology is induced in 
AD (Alonso et. al, 2001; Goedert and Spillantini, 2006).  
 
 
Figure 8: Diagram of Phosphorylation Sites on Full-Length Tau Protein.   
Diagram of the full-length tau protein (horizontal line), illustrating several of the 
serine/threonine phosphorylation sites.  The white boxes represent the 4 microtubule 
binding repeats, and the arrowhead shows where exon 10 is in human tau.  In a healthy 
brain, tau is phosphorylated at 8-10 of these sites at any given time (Figure from 
Augustinack and Schneider, 2002).   
 
 
 Specific examples of residues known to be hyperphosphorylated in PHF of AD brains 
include serines 199, 202, 235, 262, 396, 404, and threonines 205 and 231 (Goedert et al., 1994; 
Mondragón-Rodríguez et al., 2008).  In this thesis, we chose to analyze phosphorylation at three 
of these sites via two separate antibodies that recognize phosphorylation at specific sites (ser. 
199/202 and ser. 396).  These residues were most consistently mentioned in the literature as 
being hyperphosphorylated in PHF AD tau, so we felt it logical to analyze Aβ-induced or hEPN-
1 blocked hyperphosphorylation at these sites.  
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Figure 9: Flowchart of the Main Events Which Lead to Abnormal Tau Protein and 
NFTs.   
Abnormal events in a AD brain cause serine/threonine sites to become 
hyperphosphorylated, as indicated by yellow circles along the length of the protein (top).  
Hyperphosphorylation can possibly cause a conformational change in the protein, likely 
causing it to unfold.  The unfolding of the C-terminal end exposes cleavage sites, and the 
C-terminus can then be truncated by various proteases (truncation site shown by red 
lightning bolt).  Truncated tau can more rapidly form PHF/SF tau, which eventually 
results in aggregation of protein within a neuron to form NFT’s (figure adapted from 
Goedert, 1999; Augustinack and Schneider, 2002; Mondragón-Rodríguez et al., 2008). 
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After studying NFTs from AD brains, researchers observed that the hyper-
phosphorylation of tau can lead to conformational changes in the full length Tau protein, which 
in turn exposes sites on the C-terminal end to cleavage by various proteases (Figure 9).  While 
caspases are known executioners of cell death, recent research has shown that caspases are also 
involved in the abnormal processing of tau protein.  Evidence shows that tau cleaved by caspases 
can catalyze tau filament formation, can assume a conformation that has been observed in early 
NFTs, and can be hyperphosphorylated (Rissman et al., 2004).  Studies have demonstrated that 
full-length tau is cleaved in vitro by caspases-1, -3, -6, -7, and -8; however, caspases-3, -7, and -8 
cleave tau the most efficiently at the C-terminus, and caspase-6 has been implicated in cleavage 
of the N-terminus (Gamblin et al., 2003; Horowitz et al., 2004; Rissman et al., 2004).  Once tau 
is truncated through caspase cleavage, it becomes more neurotoxic as it can more readily arrange 
into paired helical filaments (PHF) and straight filaments (SF) (Abraha et al., 2000; Gamblin et 
al., 2003) (Figure 9).  Additionally, caspase-cleaved tau has been observed at high levels in AD 
brains (Rissman et al., 2004).  Thus, caspases are not only directly involved in neuronal cell 
death, but also play an important role in creating dangerous forms of tau that eventually lead to 
NFTs, and may bridge the gap between Aβ- and tau-induced neurodegeneration.    
 
AD Therapeutics 
Since there is not a cure for AD, researchers worldwide are working to develop 
therapeutic agents that will help reverse signs of the disease.  While there are currently a handful 
of FDA-approved drugs on the market, these only treat symptoms of the disease and may slow 
down the neurodegeneration process (Table 1).  However, they do not reverse neurodegeneration 
and are by no means a cure.  Many of these treatments work by inhibiting the enzyme 
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acetylcholinesterase.  Acetylcholine is an important neurotransmitter in the brain which allows 
signals to travel between neurons.  Acetylcholinesterase is an enzyme which degrades 
acetylcholine, and in AD, acetylcholinesterase is more active, thus more acetylcholine is 
degraded.  With a lack of this important neurotransmitter, the brain cannot send signals as 
effectively, and it is thought that the unused neurons eventually degenerate.  Therefore, while 
inhibiting the activity of acetylcholinesterase might allow for signals to be sent more efficiently, 
it does not prevent neurons from degenerating due to Aβ and tau pathology.  Because of this 
shortcoming, therapeutics must be developed which attack at one or several points of the 
mechanism of the disease. 
Table 1: The Current FDA-Approved Alzheimer's Drugs.   
The drugs are listed in order of the year in which they were approved.  Details show what type of drug 
each one is, as well as how each acts to help alleviate symptoms of Alzheimer’s disease.  Note that 4 out 
of 5 of these drugs is a cholinesterase / acetylcholinesterase inhibitor.  Razadyne, however, also acts to 
stimulate acetylcholine release to bolster the effects of inhibiting acetylcholinesterase.  Also note that 
Namenda antagonizes the NMDA receptor by blocking excitotoxic Glutamate binding and ionic calcium 
influx (Table adapted from www.neurotransmitter.net).  
 
Drug Action Details
Cognex® (tacrine – 1993) Cholinesterase inhibitor Reversible, competitive/non-
competitive inhibition
Aricept® (donepezil – 1996) Acetylcholine esterase 
inhibitor
Reversible, competitive/non-
competitive inhibition
Exelon® (rivastigmine - 2000) Cholinesterase inhibitor Non-competitive, slowly 
reversible
Razadyne® (galantamine - 2001) Acetylcholine esterase 
inhibitor; acetylcholine 
stimulator
Competitive inhibitor; also 
binds nicotinic receptors, 
stimulates more ACh release
Namenda® (memantine - 2003) NMDA receptor antagonist Binds NMDA receptor and 
blocks Glu binding; blocks 
Ca++ influx
27 
One recent new method was to use anti-Aβ antibodies as a vaccine to decrease levels of 
soluble and insoluble Aβ by inducing a cellular response for clearance of the peptide.  Initial 
trials in mice proved this method to be successful, so it went into clinical trials.  However, for the 
first trial, a small number of patients experienced inflammation in the brain, so that initial study 
was halted (Hardy and Selkoe, 2002).  However, a second generation vaccine was subsequently 
developed that appears to induce no inflammation, and this is in Phase III clinical testing (Elan 
Pharmaceuticals).  Another idea that has been attempted was to use antioxidant compounds to try 
to reverse the effects of oxidative stress, but human results have not shown any clear 
improvements (Hardy and Selkoe, 2002).  Thus, it remains imperative to continue to conduct 
research with the goal of reversing some of the pathology seen in AD. 
Recently, a group from Germany has shown that using sterol-linked, membrane-anchored 
β-secretase inhibitors was successful at reducing cleavage of APP by β-secretase, thereby 
reducing the levels of Aβ1-40 and Aβ1-42 secretion (Rajendran et al., 2008) (Figure 10).  Since β-
secretase activity is contingent upon endocytosis, the researchers thought anchoring the inhibitor 
to the surface of endosomes would greatly increase the inhibitor’s efficiency.  Indeed, when 
compared to free inhibitor, the sterol-linked/anchored inhibitor was able to reduce APP cleavage 
by β-secretase by about 80%.  Furthermore, the researchers looked at cleavage of APP by α-
secretase, which does not produce toxic Aβ.  α-secretase activity occurs at the cell membrane and 
not within endosomes, so the sterol-linked inhibitor did not sufficiently inhibit α-secretase, 
whereas free-inhibitor was adequate to inhibit the enzyme (Rajendran et al., 2008).  This data 
shows that a membrane-tethered, sterol-linked inhibitor is specific to curbing only β-secretase 
activity.  Such specific secretase inhibitors could quickly become new, targeted therapeutics for 
the treatment of AD.  
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Figure 10: Reduction of Aβ Formation by Sterol-Linked β-Secretase Inhibitor.   
Green in picture on the left represents Aβ in untreated cells, whereas cells treated with sterol-linked β-
secretase inhibitor (right) lack Aβ, suggesting that the inhibitor is successful at blocking Aβ production 
through APP cleavage by β-secretase (From Science, April 25, 2008). 
 
 
Ependymin Neurotrophic Factor Mimetic 
 One idea for a therapeutic agent comes from studies using fragments of ependymin 
(Shashoua et al., 2001, 2004; Adams et al., 2003).  Ependymin is a glycoprotein that was first 
discovered in the brain extracellular fluid (ECF) and cerebrospinal fluid (CSF) of goldfish in 
1976, by Victor Shashoua (Shashoua et al., 2001; Parikh, 2003).  Research has shown that 
ependymin is likely a neurotrophic factor involved in nerve regeneration and long-term memory 
consolidation (Shashoua et al., 2001; Adams et al., 2003).  In addition to goldfish ependymins, 
mammalian ependymin-related proteins (MERPs) have also been identified in humans, mice, and 
monkeys (Apostolopoulos et al., 2001).     
The knowledge that ependymin could promote nerve regeneration prompted our 
laboratory and our collaborators at Biotherapeutix, Inc. (Brookline, MA) to investigate the 
effects of human ependymin in vitro on cultured cells modeling AD.  Short, synthetic ependymin 
peptides are used because full-length ependymins are unable to cross the blood brain barrier in 
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vivo; if these peptides are to be used in vivo, they must be able to penetrate into the brain.  
Previous studies by Adams and colleagues (2003) and Shashoua and colleagues (2004) 
demonstrated that two synthetic goldfish ependymins, CMX-8933 and CMX-9236, were capable 
of inducing neuroprotective mechanisms in vitro and in vivo.  CMX-8933 (KKETLQFR) has 
been implicated in activating the AP-1 transcription factor (involved in brain injury repair) and in 
increasing levels of the anti-oxidant enzymes SOD (superoxide dismutase), CAT (catalase), and 
GPX (glutathione peroxidase) (Shashoua et al., 2001, 2004; Adams et al., 2004).  CMX-9236 
(KKDGDGDFAIDAPE) is also able to upregulate SOD, CAT, and GPX, and is neuroprotective 
in cerebral ischemia models (Shashoua et al., 2003; 2004).   
Since goldfish ependymin mimetics worked to induce neuronal cell survival, the next 
step was to experiment with human ependymin mimetics.  Thus, our lab currently works with 
derivatives of human ependymin-1 (hEPN-1) as therapeutic agents in mammalian tissue culture 
models of AD.  Previous studies using cultured human SHSY neuroblastoma cells treated with 
the Aβ25-35 and hEPN-1 mimetics, showed a partial restoration of cell survival compared to those 
treated only with Aβ (Stovall, 2006) (Figure 11).   
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Figure 11: Partial Restoration of Cell Survival In Vitro With hEPN-1 Treatment of Cultured 
Neuronal Cells.   
A. Microscopy showing differences between cells treated with the Yankner peptide versus Yankner + 
hEPN-1.  hEPN-1-treated cells physically look like control cells, as compared to Yankner only treated 
cells. B. Quantification of cell viability counts.  hEPN-1 treated cells have counts similar to the controls, 
and viable cell numbers are significantly higher than cells treated with Yankner but no hEPN-1. 
 
Additionally, cultured human SHSY neuronal cells insulted with Aβ have shown higher 
cellular levels of procaspases-2 and -3 proteins, whereas cells treated with both low and high 
doses of hEPN-1 show decreased protein levels of procaspases-2 and -3.  Preliminary 
experiments also showed an elevated caspase-3/7 enzyme activity with Aβ insult, and a 
decreased activity with hEPN-1 treatment.  Overall, these results suggest that following hEPN-1 
treatment, fewer cells were succumbing to apoptosis and degeneration, and that hEPN-1 may 
promote neuronal cell survival or block apoptosis (Kapoor, 2007) (Figure 12). 
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Figure 12: Procaspase-3 Levels and Activity After Aβ and hEPN-1 Treatments.   
A. Levels of procaspase-3 increased following Aβ treatment, and decreased after treatment with Aβ + 
hEPN-1; the 150 µM hEPN-1 dose gave the greatest decrease in procaspase-3 levels. Kapoor results were 
also similar for procaspase-2 levels. B. Caspase activity is greatly increased when Aβ is added to the 
cells, and significantly decreased after the cells are also treated with hEPN-1. 
 
  
A B
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Thesis Purpose 
As discussed in the Background, tau hyperphosphorylation has been shown to be a 
required step for the Aβ-induced neurodegeneration seen in transgenic AD mice.  This thesis 
investigated tau phosphorylation at 4 key sites in our in vitro model for AD in which Aβ25-35 is 
added to human or mouse neuronal cells in culture.  Also investigated was whether hEPN-1 
decreased any observed tau phosphorylation.  Furthermore, in vivo tau phosphorylation was 
investigated using brain lysates prepared from transgenic AD mice treated with vehicle (negative 
control) or hEPN-1.  We hypothesized that Aβ25-35 would induce the phosphorylation of tau at 
specific sites, and that treatment with hEPN-1 would reverse this upregulation.  We also 
hypothesized that hEPN-1 would lower the levels of tau phosphorylation in vivo.   
 This thesis also extended a previous thesis in our laboratory by Varun Kapoor (2007), 
who showed increased cellular levels of caspases-2 and -3, and an increase in caspase-3/7 
activity in the in vitro AD model in the presence of Aβ25-35, and reduction of cellular caspase 
levels and caspase activity following hEPN-1 treatment.  Additionally, he preliminarily 
identified increased protein levels of caspase-7 in AD mice and decreased caspase-7 levels in 
hEPN-1 treated mice.  Such caspase data could correlate with tau phosphorylation since certain 
caspases, i.e. caspase-7, have been shown to be involved in the abnormal processing of tau.   
Caspase-7 is an end-stage effector caspase activated by a variety of cell death pathways, so it is a 
good apoptotic marker.  Continuing Varun’s in vivo caspase-7 work, we hypothesized that 
caspase-7 protein levels would be low in wild type mice controls, higher in transgenic AD 
vehicle-treated mice, and reduced in AD hEPN-1-treated mice.  
Finally, this thesis investigated nuclear DNA fragmentation using TUNEL staining as a 
measure of apoptosis, to verify in our in vitro model that treatment with Aβ25-35 indeed induces 
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apoptosis, and to test the effects of hEPN-1 on DNA fragmentation.  DNA fragmentation is a 
late-stage event in apoptosis, so the presence or absence of fragmented DNA should be a reliable 
indicator of whether neuroblastoma cells are undergoing apoptosis in our experiments.  We 
hypothesized that nuclear DNA fragmentation would increase in cells exposed to Aβ, and 
decrease in Aβ-treated cells also treated with hEPN-1.   
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Materials and Methods 
Mouse Neuroblastoma-2a Cell Culture 
Mouse neuroblastoma-2a (N2a) cells were purchased from ATCC (#CCL-131).  Culture 
medium included 500 mL stock DMEM (Invitrogen #11995-073), 50 mL fetal bovine serum 
(FBS, Gibco, ATCC, or Hyclone) to give a 10% final concentration, 5.5 mL of 10 mM MEM 
essential amino acids (Gibco) to give a 0.1 mM final concentration, and 0.278 mL of 10 mg/mL 
gentamycin (Gibco) to give a 5 µg/mL final concentration.  Stock DMEM, FBS, MEM essential 
amino acids, and gentamycin were added to a 0.2 µm filtration flask, carefully pipetted up and 
down to mix, and filtered.   Media was stored at 4°C. 
Mouse N2a cell stocks were stored in liquid nitrogen.  To thaw, the cells were placed in a 
37°C water bath for 1-2 minutes, or until completely thawed.  Cells were carefully resuspended, 
and then transferred into a 15 mL conical tube where 10 mL of pre-warmed medium was slowly 
added over the course of 2-3 minutes.  Cells were centrifuged for 5 minutes at about 100 x g.  
Medium was aspirated from the tube, and the cell pellet was re-suspended in 4 mL of culture 
medium.  This was then transferred to a T25 flask and placed in a 37°C + 5% CO2 humidified 
incubator.  Cells were maintained every 3-4 days, depending on the cell density in the flask.  
Cells were fed by simply aspirating the old medium and replacing it with a fresh 4 mL of 
medium.  Cells were split at either a 1:3 or 1:4 ratio, either by scraping or trypsinizing to remove 
the cells from the surface of the flask.  
 
 
35 
Human SH-SY5Y Cell Culture 
 Human SH-SY5Y neuroblastoma cells (abbreviated SHSY) were purchased from ATCC 
(#CRL-2266).  Culture medium included 500 mL of DMEM-F12 (ATCC #30-2006), 50 mL of 
FBS (Gibco, ATCC, or Hyclone) to give a final concentration of 10%, and 0.275 mL of 10 
mg/mL gentamycin (Gibco) to give a final concentration of 5 µg/mL.  Stock DMEM-F12, FBS, 
and gentamycin were added to a 0.2 µm filtration flask, mixed, and filtered.  Medium was stored 
at 4°C.  SHSY cell stocks were stored in liquid nitrogen; cells were thawed according to the 
procedure listed above.  Cells were maintained every 2-3 days, depending on the cell density in 
the flask.  Maintenance was conducted in the same manner as previously described, however 
cells were split at a 1:2 ratio.   
 
Yankner Peptide 
Yankner peptide (Aβ25-35) was obtained from CS Bio Company (Menlo Park, CA) or was 
provided by Biotherapeutix, Inc. (Brookline, MA).  The peptide was stored as a dry powder at  
-20°C.  For experiments, 1 mg (943 nmol) of the peptide was weighed and mixed with 0.94 mL 
of 1 mM sodium bicarbonate (NaHCO3), to make a 1 mM stock.  To dissolve the powder, the 
solution was sonicated for 30-60 seconds.  Yankner peptide was used at a final concentration of 
20 µM (Yankner et al., 1990), which was sufficient for producing neurotoxic effects.  
 
hEPN-1 Peptides 
Various human ependymin-1 peptides representing different proprietary salts of the same 
amino acid sequence, were obtained from CS Bio Company (Menlo Park, CA) or from 
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Biotherapeutix, Inc. (Brookline, MA).  Peptides were initially stored as dry powders, either at 
room temperature, 4°C, or -20°C, to test drug stability at a variety of temperatures.  Peptides 
were reconstituted in DMEM, usually to make a 3.75 mM stock, and vortexed to dissolve.  Once 
reconstituted, all peptides were stored at -20°C.  For experiments, hEPN-1 peptides were 
generally used at a 150 µM concentration, 40 µl of peptide per 1 mL of medium. 
 
Cell Plating Experiments 
Cells were plated in T25 flasks at densities to give approximately 80% confluency after 
72 hrs (usually about 1.0-2.0 x 105 cells/mL for N2a’s, and 5.0-5.5 x 105 cells/mL for SHSY’s).  
To determine appropriate cell densities, cells were stained for trypan blue exclusion, then 
counted using a hemacytometer.  Cells that appeared brownish with a blue halo (blue exclusion) 
were considered viable, whereas cells stained blue were considered non-viable.  The average 
number of viable (live) cells was used to determine plating density, and cells were plated in a 
total volume of 4 mL.  Some flasks received Yankner peptide at a final concentration of 20 µM 
(80 µl of 1 mM stock) at time of plating.  Also at time of plating, some flasks received hEPN-1 
peptide (160 µl of 3.75 mM per 4 mL medium to make 150 µM final concentration).  For time 
course experiments, no Yankner was added to the 0 hour time point.  Cells were incubated for 
various time points (0, 6, 18, 24, 48, and 72 hours), then lysed (see below) at each time point.  
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Preparation of Whole Cell Extracts 
Lysates 
Cells were harvested from a flask by using a plastic cell scraper to remove them from the 
flask surface into the medium and placing them into a 15 mL conical tube.  Tubes were spun at 
500 x g for 5 minutes to obtain a cell pellet.  The old medium was removed from the pellets, and 
the pellets were washed in 1 ml of 1X PBS.  The cells were transferred to 1.5 mL microfuge 
tubes, and spun for 30 seconds at high speed.  The PBS was removed, and 200 µl of Lysis Buffer 
(20 mM HEPES pH 7.9, 10 mM KCl, 300 mM NaCl, 1 mM MgCl2, 0.1% Triton X-100, 20% 
glycerol) 10 mL stock solution, 100 µl of 50 mM DTT (Gibco), 100 µl of 50 mM PMSF 
(phenylmethylsulfonyl fluoride, Sigma) was added to each pellet.  The tubes were vortexed to 
mix, and then placed on ice for 15 minutes to swell the cells and complete the cell lysis (tubes 
were periodically vortexed during this incubation).  Finally, the lysates were centrifuged at high 
speed for 5 minutes at 4°C for clarification.  Lysates were stored at -80°C. 
Protein Determination by Bradford Assay 
Bradford assays were conducted to determine the relative protein concentrations in each 
lysate sample, compared to a BSA standard curve.  A series of BSA standards were prepared by 
adding 800 µl of 2.0 mg/mL BSA (Pierce) to the 40 µg/mL tube, and bringing the volume to 40 
mL with sterile dH2O.  20 mL from this tube was transferred into the 20 µg/mL tube, and the 
volume was again brought to 40 mL with dH2O.  Serial dilutions were conducted in this manner 
until the last tube contained a concentration of 1.25 µg/mL BSA, for a total of 6 standards (1.25, 
2.5, 5, 10, 20, and 40 µg/mL).   
0.5 mL of each BSA standard was mixed with 0.5 mL of Coomassie Protein Assay 
Reagent (Pierce), and a blank was prepared using 0.5 mL dH2O with 0.5 mL of Coomassie 
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Reagent.  The samples were prepared by adding 5 µl of cell lysate (or 1 µl for brain extracts) to 
0.5 mL of dH2O, and mixing with 0.5 mL of Coomassie Reagent.  All tubes were placed at 37°C 
for about 1 minute to allow the temperatures to equilibrate.  All samples were read on a 
spectrophotometer (LKB Biochrom Ultrospec II) at 595 nm, relative to the zero using the 
water/Coomassie blank, then the standards were read to generate a standard curve.  Finally, the 
samples were read and absorbances were obtained.  These were plotted against the standard 
curve to obtain the relative amount of total protein in each lysate sample.   
 
Polyacrylamide Gel Electrophoresis (PAGE) 
Gel Composition 
The lower resolving gel was comprised of 7.6 mL of dH2O, 6.7 mL of 30% acrylamide to 
give a final concentration of 10%, 5.1 mL of 1.5 M resolving buffer to give a final concentration 
of 0.38 M, 200 µl of 10% SDS to give a final concentration of 0.1%, 400 µl of 5% ammonium 
persulfate (APS) to give a final concentration of 0.1%, and 10 µl of 100% TEMED to give a final 
concentration of 0.05%.  The total volume made was 20 mL. The upper stacking gel was 
comprised of 5.52 mL of dH2O, 1.67 mL of 30% acrylamide to give a final concentration of 5%, 
2.5 mL of 0.5 M stacking buffer to give a final concentration of 0.125 M, 100 µl of 10% SDS to 
give a final concentration of 0.1%, 200 µl of 5% APS to give a final concentration of 0.1%, and 
10 µl 100% TEMED to give a final concentration of 0.1%.  The total volume made was 10 mL.  
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Apparatus Assembly and Gel Pouring 
Two non-siliconized glass plates of differing sizes (one large, one small) were cleaned 
with ethanol.  Two plastic spacers (0.8 mm thick) with sponges on top and notches on the bottom 
were placed on either side of the large plate, and the small plate was then placed on top of the 
large plate.  A long plastic spacer with two dove-tails (0.8 mm thick) was slid into the bottom of 
the unit so that the dove-tails fit into the notches of the side spacers.  The entire unit was clamped 
together using 9 binder clips around the edges.  The unit was leaned against something, and the 
lower resolving gel was poured between the two glass plates to about 1 inch from the top of the 
smaller plate.  The resolving gel was immediately overlaid with dH2O to eliminate any bubbles 
that may have formed during pouring, and to help produce a straight edge at the top of the gel.  
The gel was left to solidify for approximately 20 minutes. 
Once the gel was solid, the dH2O overlay was discarded, and the upper stacking gel was 
poured to the top of the smaller plate, filling in the rest of the space between the two plates.  A 
20-tooth plastic comb was placed in the top of the stacking gel to form 20 wells in the gel.  This 
assembly was left to solidify for approximately 20 minutes.  Once solid, the comb was carefully 
removed, the bottom gasket was removed, and the unit was placed into a V-16 electrophoresis 
chamber (BRL) with the smaller plate facing the inside of the chamber.  Protein electrode buffer 
(final concentrations 25 mM tris, 0.192 M glycine, 0.1% SDS, dH2O to make 10 L) was poured 
into the top and bottom sections of the electrophoresis chamber so that the electrodes were 
covered.  Gels were pre-run for 30-60 minutes to equilibrate it with the buffer.  
 
Sample Preparation and Gel Loading 
Previously prepared whole cell extracts were used for PAGE.  From the Bradford Assay 
data, the amounts of sample required for a specified protein load (see individual figure legends 
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for final mass) were determined.  Each sample had a final volume of 20 µl and was comprised of 
cell extract, 5 µl of 4X sample buffer (0.5 M stacking gel buffer, 8% SDS, 20% glycerol, 40% β-
mercaptoethanol, and 0.4% bromophenyl blue) and dH2O to bring the volume to 20 µl.  dH2O 
was added to the 0.5 mL microfuge tubes first, followed by the 4X sample buffer and then the 
extract.  A Kaleidoscope Pre-Stained multicolor standard (Biorad) was prepared using 4 µl of 1X 
sample buffer and 4 µl of the standard.  The Biotinylated Broad Range standard (Biorad) was 
prepared using 10 µl of 1X sample buffer and 1 µl of the standard.  All samples and standards 
were boiled for 2 minutes to ensure protein denaturation.  Then, all samples and standards were 
quickly centrifuged before loading onto the gel.  Gel loading tips were used to carefully load 20 
µl of the Kaleidoscope standard and all samples into respective wells.  11 µl of the Biotinylated 
standard was loaded into its respective well.  Gels were run at approximately 150 volts for 3 
hours.   
Gel Transfer to Membrane 
Once the gel was finished running, the unit was disassembled so the gel remained on one 
of the glass plates.  The stacking gel, as well as any excess from the sides and bottom, were 
removed.  A piece of nitrocellulose membrane (Whatman, 0.45 µm pore size) was cut to fit the 
size of the gel, and two pieces of gel blotting paper were also cut accordingly.  The membrane 
was wet in pre-chilled transfer buffer (48 mM tris, 39 mM glycine, 0.037% SDS, 20% methanol) 
laid over the gel, and carefully smoothed out to eliminate bubbles.  One piece of filter paper was 
wetted in transfer buffer and placed over the membrane.  The gel was then laid on a transfer 
sponge, and the sponge was placed so that the membrane would be oriented towards the positive 
side of the transfer complex.  The other filter paper was wetted and placed on top of the gel, the 
second transfer sponge placed over this, and the other side (negative) of the plastic transfer 
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apparatus locked into place.  The entire transfer complex was then placed into the electrophoresis 
chamber with the negative side facing the front of the chamber.  Proteins were transferred to the 
membrane at approximately 50 volts for 2 hours, at 4°C with stirring.  
 
Blocking and Antibody Incubations: 
Membrane Blocking 
After protein transfer to membrane, the transfer complex was disassembled and the 
membrane placed into block solution prepared the day prior (1% casein, 1X PBS, 0.2% Tween- 
20) with the side that was touching the gel facing up.  Membrane was blocked for at least 1 hour 
at room temperature with rocking, or overnight at 4°C with rocking. 
Antibody Incubations 
For primary antibody incubations a piece of heat-sealable plastic was cut slightly larger 
than the size of the membrane and sealed on 3 edges.  The membrane was placed into the plastic 
pouch, followed by 3 mL of block solution.  If testing for phosphorylated tau, 3 µl of antibody, 
either anti-tau [pSpS199/202] (Biosource #44-768G) or p-Tau Ser 396 (Chemicon International 
#AB-9658) was added to the block solution to make a 1:1000 dilution.  The final edge of the 
pouch was sealed off and all bubbles were removed from the side of the membrane that was 
originally touching the gel.  This was placed on a rotating “Nutator” for 2 hours at room 
temperature.  If detecting β-tubulin, 6 µl of 500 µg/ml anti-β-tubulin (Imgenex #IMG-5810A) 
was added to the 3 mL of block solution, to give 1 µg/mL concentration.  Finally, if detecting 
caspase-7, 3 µl of anti-caspase-7 (Imgenex #IMG-5560) was added to 3 mL block solution to 
give a 1:1000 dilution.   
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For all secondary antibody incubations, goat-anti-rabbit HRP (Pierce) and streptavidin 
HRP (Pierce) conjugates were used at dilutions of 1:1000.  The membrane was placed in a small 
plastic container, block solution was added, and the appropriate amount of both conjugates was 
added to make a 1:1000 dilution (generally 20 µl secondary antibody in 20 mL block solution).  
This container was placed on a rocker shaker for 2 hours at room temperature.  Note that the 
membrane was washed after both primary and secondary antibody incubations with PBS-Tween 
under vigorous shaking conditions, and washed with PBS before detection. 
 
Chemiluminescent Detection and Development 
Chemiluminescent Detection 
SuperSignal West Pico chemiluminescent substrate (Pierce) was used to detect protein 
presence by combining equal amounts of Stable Peroxidase Solution and Luminol/Enhancer 
Solution just prior to use, and incubating the membrane in the substrate solution for 5 minutes in 
the dark at room temperature.  After 5 minutes, the substrate was allowed to drip from the 
membrane before it was placed between two plastic sheets in a film cassette, but the membrane 
was not allowed to dry. 
Film Development 
In the darkroom, a piece of Biomax XAR film (Kodak) was placed over the membrane in 
an aluminum film cassette, and was exposed for the desired amount of time.  Film was either 
developed manually or via the Kodak M35A X-Omat Processor.  If done manually, the film was 
placed in GBX developer solution (VWR) for 5 minutes with initial agitation only, to allow the 
image to fully develop.  Once finished, the film was submerged in tap water to rinse off the 
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developer, and subsequently placed in fixative (VWR) for 3 minutes, with intermittent agitation 
(approximately every 30 seconds).  Once finished, the film was again submerged in water and 
agitated to thoroughly rinse off the fixative, and then was allowed to air dry.  If film was 
developed using the processor, film was placed in the feed tray of the processor where it was 
automatically taken into the machine, was passed through the machine (about 2 minutes), and the 
developed film was retrieved from the catch tray.     
 
TUNEL Assay 
 TUNEL (Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling) 
assays were performed to determine amount of fragmented DNA in control, Aβ-treated, and Aβ 
+ hEPN-1 treated cells.  SHSY cells were seeded in either 24-well microtiter plates at a 
concentration of about 1.7 x 104 cells in 1 mL, and incubated for approximately 24-hours before 
peptides were added.  After 24-hours, Aβ25-35 was added to 20 µM, and various hEPN-1 peptides 
were added simultaneously to 150 µM.  For post-insult hEPN-1 addition experiments, 150 µM 
hEPN-1 was added 3 and 6 hours post Aβ addition.  Cells were allowed to incubate with the 
peptides for approximately 24-hours before collection.   
Cells were collected by trypsinization, and spun down in Eppendorf tubes for about 5 
minutes at 7,000 rpm.  Cells were washed once in 50 µl 1X PBS, quickly spun to re-pellet, and 
resuspended in 20 µl 1X PBS.  Cells were then transferred to poly-L-lysine-coated (Sigma) 
microscope slides, and allowed to air-dry for about 15 minutes in the tissue culture hood.  Once 
dried, slides were immersed in 10% neutral buffered formalin (Richard-Allan Scientific) for 25 
minutes at room temperature, for fixation.  Slides were then washed twice by immersing in 1X 
PBS for 5 minutes each, and either stored in PBS at 4°C until the next day, or immediately 
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immersed in 0.2% Triton X-100 (Sigma, diluted in 1X PBS) for 5 minutes at room temperature, 
to permeabilize the cells.  Cells were again washed twice by immersing in 1X PBS for 5 minutes 
each.   
Slides were tapped to remove excess liquid, then 100 µl of equilibration buffer (TUNEL 
kit, Promega #G-7360) was added to the area of fixed cells, and the slides were incubated at 
room temperature for 10 minutes.  Slides were blotted with a KimWipe to remove equilibration 
buffer, and 100 µl of rTdT reaction mix (TUNEL kit, Promega) was added to the cells ( 
Table 2).  A plastic cover slip (TUNEL kit, Promega) was immediately placed over the 
slide to evenly distribute the reaction mixture, and the slides were incubated at 37°C for 1 hour.  
 
TUNEL Kit Component Component Vol. per Standard 100 µl Rx. 
Equilibration Buffer 98 µl 
Biotinylated Nucleotide Mix 1 µl 
rTdT Enzyme 1 µl 
 
Table 2: TUNEL Kit Component Volumes.   
Multiply each component volume in the right column by the number of 
reactions being performed to calculate the total volume needed.  All 
components were thawed on ice, and reaction mix was kept on ice until 
applied to slides. 
 
 
After the rTdT labeling reaction, the plastic cover slips were removed, and slides were 
immersed in 2X SSC for 15 minutes at room temperature, to stop the reactions.  Slides were then 
washed 3 times by immersing in 1X PBS to remove unincorporated biotinylated nucleotides.  
Next, slides were immersed in 0.3% hydrogen peroxide (in 1X PBS) for 5 minutes to block 
endogenous peroxidases.  Again, slides were washed 3 times by immersing in 1X PBS.   
For developing the reactions, streptavidin HRP (TUNEL kit, Promega) was diluted 1:500, 
and 100 µl was added to each slide; slides were incubated for 30 minutes at room temperature.  
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Before adding DAB mixture, slides were washed 3 times by immersing in 1X PBS.  DAB 
mixture was prepared by adding 50 µl of DAB substrate 20X buffer to 950 µl of dH2O.  Then, 50 
µl of both DAB 20X chromogen and hydrogen peroxide 20X were added.  100 µl of DAB 
solution was added to each slide, and slides were incubated for 10 minutes or until a light brown 
background appeared.  Slides were rinsed several times in dH2O, 1 drop of aqueous mounting 
medium (Biomeda) was added, and cover slips were placed over cell samples.  Edges of the 
cover slips were sealed with clear nail polish and allowed to dry.  Slides were viewed at 100x 
(10x objective) magnification, and imaged on a Leica DM LB2 microscope (Glenn Gaudette) 
using the Leica Application Suite software.  
 
Mouse Study 
 Double mutant AD mice (B6C3-Tg; APPswe/PSEN1dE9) were purchased from The 
Jackson Laboratory in Bar Harbor, ME for use in this study.  These mice were maintained as 
hemizygotes at The Jackson Laboratory, and the transgene was determined to be inserted at a 
single locus.  The transgene is generally expressed in the neurons of the central nervous system.  
The APPswe mutation mimics the mutation found in the Swedish familial AD, which shows 
accelerated Aβ production.  In addition, nucleotides encoding 3 human amino acid residues were 
inserted into the mouse APP gene to result in a humanized mouse APP mutant.  The PSEN1dE9 
mutation lies within the presenilin-1 gene, and in this case exon 9 was deleted; this results in 
elevation of the γ-secretase enzyme which leads to overproduction of Aβ1-42.  In this mouse line, 
the first Aβ deposits are observed around 5-6 months of age, and are pronounced at 11 months 
(Jankowsky et al., 2001; 2004).  Behaviorally, these mutants have learning impairment (Reiserer 
et al., 2007). 
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 For our study, these mice were housed at Brigham and Women’s Hospital in Boston, 
MA, and peptide delivery by p.o. dosing was conducted by Dr. Cindy Lemere.  The mice were 
allowed to age for 8 months before any treatments were administered.  According to Jankowsky 
et al. (2001), at 8 months of age there is marked plaque formation in the hippocampus and 
cortex.  Eight-month-old mice were divided into 4 experimental groups: wild type (WT) vehicle, 
WT hEPN-1, Alzheimer’s (Alz.) vehicle, and Alz. hEPN-1.  Three mice in each group were 
tested.  The vehicle for hEPN-1 was dH2O.  For this experiment, hEPN-1 was covalently 
conjugated to a DHA carrier by BioTherapeutix to confer the ability to cross the blood-brain 
barrier.  Mice were administered 0.2 ml of 30 mg/kg dose of peptide twice daily by p.o. dosing 
for a 2 week period.  After the treatment regimen, mice were anesthetized using CO2, sacrificed 
by decapitation, and brains were perfused with PBS, split into halves, and stored at -80°C.  
 
Brain Homogenization 
 About 1 mg of brain tissue (representing about 1/4th of the entire half brain provided by 
the Lemere lab) was removed from each brain, from the approximate area of the hippocampus 
and cortex.  The tissue was placed in a small glass homogenizer, 1 mL of lysis buffer (see 
previous lysis section) was added, and tissue was homogenized using the appropriately sized 
glass dounce homogenizer.  Homogenate was then placed in a 1.5 mL Eppendorf tube on ice.  
Samples were spun for 5 minutes on high speed at 4°C.  Supernatant was collected and stored at 
-80°C. 
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Data Analysis 
 All immunoblot films were analyzed using Scion Image software (NIH) to determine the 
density of the observed bands, and results were given as OD.  In most cases, these values were 
normalized relative to the control, and reported as fold upregulation or change.  However, for the 
brain extract data, values were left as OD since there was not a distinctive control to normalize 
to.  
 TUNEL data were analyzed by capturing images of three randomly chosen optical fields 
per treatment using the Leica Application Suite software.  Images were transferred to a 
Powerpoint file, and divided into quadrants to make cell counting manageable.  Unstained and 
stained cells were counted in each quadrant, and numbers were added to obtain the total cells per 
optical field.  The values for the three optical fields were added together, and the percentage 
stained cells was determined by taking the total number of stained cells in all three fields, 
dividing by the total number of cells counted in all three fields, and multiplying by 100 to give a 
percent value.  If multiple experiments were conducted with the same conditions, the final 
percent values were averaged together for a histoplot.  Stained cells were considered those with a 
medium to dark brown appearance, whereas unstained cells were considered those with a clear to 
light brown appearance.  
 For one set of TUNEL data, a threshold indicating positive staining was used.  In Adobe 
Photoshop, the TUNEL image was changed to grayscale, and a threshold value was set so “true” 
positive staining was captured.  Threshold was set based on positive control images, and negative 
controls and treatments were compared to positive controls using this threshold value.  The 
positive particles in each image were then analyzed using the Image J software.  Parameters were 
set so that the program analyzed particles containing greater than 100 pixels.  Results were 
reported as number of particles, and numbers were compared for all treatment groups.  
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Most data were statistically analyzed using one-way Analysis of Variance (ANOVA) to 
determine the significance of results, with a confidence level of 95%.  SPSS software was used 
to perform statistical tests.  The reported results were analyzed using conservative HSD-post hoc 
tests.  Data were also analyzed using less conservative LSD post-hoc tests, but these results are 
not reported.   The more conservative test was chosen because conservative tests are less likely 
to produce a Type I error, which means it would detect a difference where no difference exists.  
Conversely, conservative tests are more likely to produce a Type II error, which means they can 
fail to detect a true difference.  If only two groups were being compared the Student’s t-test was 
used to analyze data, with a confidence level of 95%.  
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Results 
Tau Phosphorylation  
 As discussed in the Background section, tau hyperphosphorylation has been shown to be 
a required step in Aβ-induced pathology in transgenic AD mice.  Previously, our lab 
demonstrated that therapeutic hEPN-1 peptide mimetics are capable of partially restoring cell 
survival, and of lowering caspase levels and activity, in cultured Aβ-treated SHSY cells.  To our 
knowledge, however, no lab has studied tau phosphorylation in this in vitro AD model; thus, one 
of the main goals of this thesis was to investigate, in Aβ-treated cells, tau phosphorylation at 3 
key sites previously shown to be important in AD, and to determine whether our hEPN-1 
therapeutics were able to reduce tau phosphorylation in these cells.  Initially SHSY cells 
provided interesting data, but several problems occurred with the SHSY cells when repeating the 
tau experiments, so we switched to mouse N2a cells with the hope of observing similar trends as 
were seen in SHSY cells.  Additionally, the N2a cells tend to grow more quickly and can 
withstand more stress than SHSY cells, which made them relatively easy to culture and 
manipulate.  
To begin, it was necessary to determine that tau phosphorylation could be induced in N2a 
cells by any agent.  Okadaic acid (OKA), a known stimulator of tau hyperphosphorylation 
through inhibition of phosphatases (Poppek et al., 2006), was used in N2a cultures to increase tau 
phosphorylation, and to test the antibody reagents.  Indeed, 0.5 µM OKA treatment increased the 
levels of phosphorylated tau at positions ser 199/202 in N2a cells as assayed by immunoblots 
(Figure 13A, -OKA and +OKA lanes), and this signal disappeared in negative controls lacking 
primary antibody (Figure 13A, right panel).  Thus, it is clear that tau phosphorylation can be 
induced in N2a cells, and that the ser 199/202 antibody works well. 
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To test the effects of Aβ on ser 199/202, Aβ time course experiments were conducted.  
N2a cultures were exposed to 20 µM Aβ for various times, then lysates were analyzed by 
immunoblots (Figure 13A).  The data indicate the ser 199/202 signal increases as the time of Aβ 
exposure increases.  It was expected that multiple sets of bands might be detected by the anti-ser 
199/202 antibody, as it was the same antibody used by Poppek et al. (2006) and they detected 
multiple sets of bands.  It is unclear if these bands represent different degrees of phosphorylation 
or represent phosphorylation of the different tau isoforms.  Quantification of these results is 
shown in Figure 13B; the 72-hour time point gives approximately a 3-fold upregulation relative 
to the untreated sample.   
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Figure 13: Aβ25-35 Increases Tau Phosphorylation at Ser 199/202 in N2a Cells.   
Mouse N2a cells were used in an Aβ time-course to determine whether tau phosphorylation at ser 
199/202 increase with increasing times of Aβ exposure.  A. Representative immunoblot showing the 
increase in phospho-tau signal with increasing time of Aβ exposure. (-) and (+) okadaic acid controls are 
included.  Total cellular protein load for all samples was 30 µg/lane.  The 0 hour time point was an 
untreated control; all other time points were treated with 20 µM Aβ25-35 (Yankner peptide) and allowed to 
incubate at 37°C for the stated amount of time.  Anti-phospho tau [pSpS199/202] (Biosource) was used as a 
probe.  Immediately below the blot is a β-tubulin load control.  For the tubulin lanes, total cellular protein 
load was 20 µg/lane for OKA samples, and 15 µg/lane for time-course samples.  B. Quantification of the 
bands from 5 experiments, represented as fold-upregulation of phospho-tau signal compared to the 
untreated control.  There is a significant difference between the control and the 72 hr time point (p < 
0.05), as determined by one way ANOVA followed by HSD post-hoc tests. 
 
 
 As a control to ensure that tau does not naturally become phosphorylated in cells cultured 
over 72 hours due to normal cell growth and increasing cell density, experiments were run in 
parallel where one set of flasks was left untreated at all time points (control), and the other set of 
flasks was treated with Aβ as described above (experimental).  Cells from both sets of flasks 
were lysed at the appropriate time points, and a Western blot for tau phosphorylated at serines 
199 and 202 was performed (Figure 14).  In control cells (left panel), no evidence of 
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phosphorylation was observed, whereas in experimental cells (right panel), phosphorylation did 
occur, especially at the later time points.  This experiment confirms that Aβ, and not normal cell 
growth and proliferation, was the cause of phosphorylation of tau at serines 199/202 in N2a 
cultures.  
 
Figure 14: Normal Cell Growth and Proliferation Does not Cause Phosphorylation 
of Tau at Ser 199/202.   
Left panel shows the control time course, not treated with Aβ.  No tau phosphorylation 
was detected with an antibody specific to phosphorylation at serines 199/202.  Right 
panel shows the experimental time course, where cells were treated with 20 µM Aβ and 
exposed for indicated times.  Tau phosphorylation was evident, especially at the later 
time points.  Time points from each set were lysed simultaneously. 
 
When using a different p-tau antibody against serine 396, another key site, SHSY cells 
produced a band of the expected size (Figure 15A) whose intensity appeared to increase with Aβ 
treatment.  Furthermore, the band disappeared in a negative control lacking primary antibody 
(Figure 15A, lower panel).  Because of various problems with the SHSY cell line, only two 
repetitions of this experiment were conducted.  Both blots are shown (Figure 15A), and results 
from both experiments were quantified (Figure 15B).  However, using a conservative Tukey 
HSD post-hoc analysis, the increase was not statistically significant due to the lack of enough 
data, while the increase was significant using the less conservative LSD post-hoc test.  Thus, Aβ 
appears to increase tau phosphorylation at serine 396 in SHSY cells, although the data were not 
quite significant using the more conservative test.  
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Figure 15: Aβ25-35 Increases Tau Phosphorylation at Ser 396 in SHSY Cells.   
A. Top two blots: two immunoblots for p-tau serine 396 showing a visual increase as Aβ exposure time 
increases.  Third panel, β-tubulin load control.  Bottom panel, negative control lacking primary antibody.  
Total cellular protein loads were 20 µg/lane for pTau serine 396 blots, and 15 µg/lane for β-tubulin blot.  
B. Quantification of the two ser 396 blots in A.  Trend shows an increase in signal.  Error bars represent 
the range in the data.  
 
To test whether hEPN-1 decreases tau phosphorylation in Aβ-treated cells, N2a 
experiments were performed at 72 hours, the optimal time observed in the previous experiments.  
Three flasks of cells were tested: untreated control, Aβ-treated, and Aβ + hEPN-1 treated.  At the 
end of the 72-hour incubation, cell lysates were analyzed for p-tau serine 199/202 (Figure 16A).  
The representative immunoblot showed higher levels of phosphorylated tau in Aβ-treated cells 
compared to both controls, and this signal decreased in cells also treated with hEPN-1 (Figure 
16A).  After performing 4 repeat experiments, although the observed results were not statistically 
significant using the more conservative HSD post-hoc analysis, they were significant using the 
less conservative LSD post-hoc analysis, and the means demonstrated a clear trend (Figure 16B).  
The Aβ + hEPN-1 treated cells were statistically indistinguishable from the control (Figure 16B), 
indicating that hEPN-1 may be able to reduce tau phosphorylation at serines 199/202.  Further 
optimizing this experiment may lead to more significant data.  
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Figure 16: hEPN-1 Treatment Lowers Tau Phosphorylation at Ser 199/202 in N-2a 
Cells.     
A. Immunoblot showing a slight increase in p-tau ser 199/202 signal in cells treated with 
Aβ, and a reduction in that signal in cells simultaneously treated with hEPN-1. Protein 
load for p-tau blot was 15 µg/lane, and 20 µg/lane for β-tubulin blot. B. Quantification of 
4 separate experiments.  No significant differences are observed at this time using 
conservative HSD post-hoc tests, however the means illustrate a clear trend.   
 
Since hEPN-1 was somewhat successful at lowering tau phosphorylation in vitro, we 
tested whether similar results could be obtained in vivo.  Double mutant AD mice originally 
derived in David Borchelt’s laboratory (Jankowsky et al., 2001; 2004) were purchased 
commercially.  These mice are transgenic for two mutant genes: human APP mutated to mimic 
the Swedish AD mutation, which accelerates the production of Aβ1-42, and a presenilin mutation 
(exon-9 deletion) that increases the activity of gamma-secretase to further accelerate Aβ1-42 
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production.  Both transgenes are predominately expressed in the central nervous system.  The 
first Aβ deposits are observed around 5-6 months of age, and are pronounced at 11 months 
(Jankowsky et al., 2001; 2004).  Behaviorally, these mice are learning-impaired (Reiserer et al., 
2007).  For our study, the mice were aged to 8 months, a time at which clear plaque production is 
evident in the hippocampus and cortex.   
Immunoblots to detect phosphorylated tau protein in mouse brain extracts were 
conducted to look for differences in wild type (WT) versus transgenic AD (Alz) mice.  Both WT 
and Alz mice were treated as described in Materials and Methods, and brains were collected and 
homogenized.  Levels of tau phosphorylation were first assessed using the antibody to p-tau ser 
199 and 202 (Figure 17).  The means showed a clear reduction in levels of phosphorylated tau in 
hEPN-1 treated Alz mice compared to vehicle treated Alz mice.  At this time, the decrease is not 
statistically significant according to a Student’s t-test (p = .216), the results showed that 
Alzheimer’s mice treated with hEPN-1 appear to have lower levels of p-tau Ser 199/202 than 
Alzheimer’s mice treated only with vehicle.   
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Figure 17: Reduction in Tau Phosphorylation at Ser 199/202 in hEPN-1-Treated Alzheimer's Mice. 
A. Upper panel, p-tau 199/202 blot.  First 3 lanes show vehicle-treated Alz mice, and last 3 lanes show 
hEPN-1-treated Alz mice.  Protein load for p-tau blot was 25 g/lane, and for β-tubulin blot was 15 g/lane. 
B. Quantification of the bands on above blot.  While no significant differences can be seen at this time 
using the Student’s t-test, hEPN-1 shows a trend of lowering phosphorylated tau protein levels in Alz 
mice.  
 
 
In addition to using the antibody for p-tau ser 199/202, we also tested p-tau ser 396 
(Figure 18).  Indeed, this antibody rendered similar results where the means appeared to be lower 
in hEPN-1-treated Alz mice than in vehicle-treated Alz mice.  Using either antibody, the wild 
type mouse control data were inconsistent in the sense that great variation between animals was 
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observed and signals were higher than expected; therefore, the data are not shown. 
 
Figure 18: Reduction in Tau Phosphorylation at Ser 396 in hEPN-1-Treated Alzheimer’s Mice. 
A. Upper panel, p-tau Ser 396 blot.  First 2 lanes show vehicle-treated mice, and last 2 lanes show hEPN-
1-treated mice.  Protein load for p-tau blot was 20 ug/lane, and for β-tubulin blot was 15 ug/lane. B. 
Quantification of the bands on above blot, illustrating that hEPN-1 appears to show a clear trend of 
lowering p-tau Ser 396 protein levels in hEPN-1-treated Alzheimer’s mice.  
 
TUNEL Assay for Apoptosis 
 
 Another goal of this thesis was to use TUNEL staining to investigate nuclear DNA 
fragmentation in our in vitro AD model.  TUNEL (Terminal Deoxynucleotidyl Transferase 
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Biotin-dUTP Nick End Labeling) staining  works by measuring fragmented DNA through 
incorporation of a biotinylated nucleotide at the 3`-OH ends of DNA, catalyzed by the 
Recombinant Deoxynucleotidyl Transferase (rTdT) enzyme.  When streptavidin HRP is added, it 
binds to any areas containing biotinylated nucleotide, then diaminobenzidine (DAB) is used to 
detect DNA ends.  Any cell containing fragmented DNA would have a greater number of 3’ 
DNA ends, and should stain brown, thus representing apoptosis (Promega DeadEndTM 
Colorimetric TUNEL System Technical Bulletin, 2005).  In preliminary experiments, where only 
untreated control and Aβ-treated cells were tested, results showed that apoptosis occurred when 
cells were exposed to 20 µM Aβ for approximately 24-hours (Figure 19).   
 
Figure 19: Data from Preliminary TUNEL Assay.   
A. Microscope images (100x magnification) of untreated control and Aβ-treated SHSY cells following 
TUNEL staining.  Dark brown stain represents fragmented DNA, a late-stage signature of apoptosis.  
Higher levels of brown staining were observed in Aβ-treated cells versus untreated controls. B. 
Quantification of stained cells in control and Aβ-treated cells viewed in 3 randomly chosen optical fields.  
Results are expressed in terms of the percentage brown stained out of the total number of cells counted 
per optical field.  Data represent one trial. 
 
Once we determined that TUNEL staining works to detect Aβ-induced apoptosis in 
cultured SHSY cells, experiments were conducted to test whether various hEPN-1 peptides 
prevent apoptosis in Aβ-treated cells (Figure 20).  Specifically, 4 variations of hEPN-1 
(synthesized in various proprietary salts to determine which salt produces the most stable drug) 
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were tested, and all showed a clear decrease in apoptotic cells compared to Aβ-treated cells.  All 
hEPN-1-treated samples were statistically indistinguishable from control cells using both HSD 
and LSD post-hoc analysis.  Conservative HSD post-hoc analysis showed that Aβ samples were 
not significantly different from the other samples, but the difference was significant using the 
less conservative LSD post-hoc analysis.  These results were determined via the cell counting 
method described in the Data Analysis section of Materials and Methods.   
 
Figure 20: TUNEL Assay Showing Various Salts of hEPN-1 Prevent Aβ-Induced Apoptosis in 
SHSY Cells.   
Quantified results of two independent TUNEL assays testing 4 hEPN-1 peptides’ abilities to lower or 
prevent apoptosis in the presence of 20 µM Aβ.  Slides were viewed at 100x magnification and 3 
randomly chosen optical fields were viewed for each treatment.  Apoptosis was clearly evident in Aβ-
treated cells, and was reduced in cells treated with 150 µM each of the 4 hEPN-1 peptides. 
 
  
To ensure that the cell counting method used to analyze the TUNEL data was accurate, 
the same data set represented in Figure 20 was analyzed using a threshold method.  Beginning 
with images for Aβ-treated cells (for positive staining), Adobe Photoshop was used to set a 
threshold for positive staining.  This threshold was then applied to all subsequent images, 
allowing differentiation between positive and negative staining.  Once the threshold was set for 
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all images, Image J software was used to quantify the number of positive particles (anything 
greater than 100 pixels, Figure 21).  The results are similar to those seen in Figure 20 where the 
cell counting method was used.  
 
 
Figure 21:  Analysis of TUNEL Data Using a Signal Threshold Analysis. 
In Adobe Photoshop, images of Aβ-treated cells were to set a threshold (value was 59) for positive 
staining.  Then, images for all other treatments were compared against this threshold.  Values were 
determined using Image J software by analyzing particles greater than 100 pixels.  For each image, a 
number was given corresponding to number of particles within that range.  Three images per treatment 
were analyzed and the numbers averaged to create the histoplot.  
 
In addition to experiments testing various hEPN-1 peptides added simultaneously to the 
Aβ insult, also tested was the ability of hEPN-1 to lower apoptosis when added post-insult, in 
this case 3 and 6 hours post Aβ addition.  The results again show a significant increase in 
apoptosis in Aβ-treated cells, and a significant decrease in apoptosis in all hEPN-1 treatments 
(Figure 22), as determined by one way ANOVA and HSD post-hoc analysis.  The results 
demonstrate that even when hEPN-1 is added post-insult, it may still have the ability to reduce 
apoptosis.  
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Figure 22:  hEPN-1 Can Lower TUNEL Staining Even When Added Post-Insult. 
hEPN-1 was added to 20 µM Aβ-treated cells either simultaneously (0 hr), or 3 or 6 hours post Aβ 
addition.  Total incubation time with Aβ and hEPN-1 was 24 hours.  After 24 hours, a TUNEL assay was 
performed and slides were viewed at 100x magnification.  3 randomly chosen optical fields were 
observed and photographed for each treatment in each of the 3 independent experiments.  Apoptosis was 
evident in Aβ-treated cells, and reduced in cells treated with hEPN-1 at all time points.  
 
 
 
In Vivo Caspase-7 Studies 
 Since hEPN-1 proved fairly successful in vitro at preventing or lowering Aβ-induced 
apoptosis, the next logical step was to test its efficacy in vivo.  WT and Alz Mice were treated as 
described in Materials and Methods, and brains were collected and homogenized.  Initially, we 
tested brain extracts for caspase-7 because caspase-7 is a key end-stage effector caspase and 
would likely be present in Alzheimer’s brains at fairly high levels, regardless of which cell death 
pathway was induced by Aβ.  Additionally, previous data in our laboratory (Kapoor, 2007) 
showed that a caspase-7-related protein (C7RP) interacts strongly with a caspase-7 antibody and 
disappears in negative controls lacking primary antibody.  However, C7RP is larger than has 
been reported in the literature for caspase-7, but it could be detected in mouse brain extracts by 
immunoblots whereas caspase-3 and several others were never successfully detected.  The 
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immunoblot results (Figure 23) show that C7RP levels are relatively low in wild type mice dosed 
with either vehicle or hEPN-1.  Conversely, C7RP levels are high in vehicle-dosed Alzheimer’s 
mice, and this elevated level is reduced in hEPN-1-treated Alzheimer’s mice.  One-way ANOVA 
followed by Tukey HSD post-hoc tests revealed that the vehicle treated Alz mice had 
significantly higher caspase-7 levels as compared to both WT controls.  However, it is still 
important to test more animals must in order to draw fully accurate conclusions from this data.   
 
Figure 23: Reduction in Caspase-7-Related Protein Levels in hEPN-1-Treated Alzheimer's Mice. 
Both wild type (WT) and Alzheimer’s (Alz) mice were treated with vehicle or hEPN-1, and brain extracts 
were analyzed by immunoblot for the presence of caspase-7 protein.  A. Immunoblot for caspase-7 
revealed caspase-7 related protein (C7RP) bands at about 95 kDa, with clear differences in protein levels 
between mouse groups. The protein load for both caspase-7 and β-tubulin blots was 15 µg/lane. B. 
Quantification of results from first caspase-7 blot, illustrating that levels of C7RP are low in WT controls 
and greater in Alz. vehicle-treated mice.  hEPN-1 treatment of Alz. mice decreases the levels of C7RP, 
bringing it close to control levels.   
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Discussion 
The overall goal of this thesis was to continue our laboratory’s investigation of the 
mechanisms of cellular apoptosis induced by Aβ, and to further study hEPN-1 mimetics as 
possible AD therapeutics, both in vitro and in vivo.  This thesis explored several new angles of 
the apoptotic mechanism.  We tested the hypotheses that phosphorylation of the tau protein, 
DNA fragmentation, and caspase protein expression, are induced by Aβ, and diminished by 
hEPN-1 treatment. 
 
Tau Hyperphosphorylation 
 To our knowledge, no laboratory has studied tau phosphorylation in detail using this in 
vitro AD system, so an early aspect of this thesis investigated whether insulting cells with Aβ25-35 
increased cellular levels of tau phosphorylation.  As discussed in the Background, studies have 
shown that tau becomes hyperphosphorylated in the neurons of AD brains, which ultimately 
causes the formation of neurofibrillary tangles (NFT’s) and cell death.  Transgenic Alz mice that 
produce Aβ, but are missing tau, do not develop symptoms of the disease (Rapoport et al., 2002); 
thus, tau hyperphosphorylation is thought to be essential for neurodegeneration and downstream 
from the initial Aβ insult.  Although some of the kinases responsible for tau hyper-
phosphorylation have been identified, the mechanism is unknown.  Some scientists have 
proposed that toxic Aβ oligomers may disrupt the proteasome, preventing dysfunctional and 
damaged tau (and other proteins) from being degraded.    
We chose 3 key tau phosphorylation sites, serines 199, 202, and 396, which were 
previously indicated to play a role in AD (Goedert, 1994; Augustinack and Schneider, 2002; 
Rissman et al., 2004).  Mouse N2a cells were first treated with okadaic acid, a known stimulator 
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of tau hyperphosphorylation (Poppek et al., 2006), as an initial test of our cells and tau 
antibodies.  The increased immunoblot signals for p–tau 199/202 (Figure 13A, lanes 1 and 2) 
were consistent with the Poppek data in mouse HT22 and rat PC12 neuronal cells.  Thus, we 
concluded that the N2a neuroblastoma line could be induced to undergo tau 
hyperphosphorylation, and moved on to test Aβ.  Time-course experiments in which N2a cells 
were exposed to Aβ25-35 for varying lengths of time showed that the longer cells were exposed to 
Aβ, the higher the levels of p-tau 199/202 signal observed (Figure 13A, lanes 3-8), with the 72 
hour time point giving an approximate 3-fold upregulation in tau phosphorylation, at levels 
similar to those seen in okadaic acid-treated cells.  Thus, this experiment helps validate our in 
vitro AD assay, at least partially mimicking a tau phosphorylation event seen in AD, and also 
validates our antibody.   
 Although identical p-tau 199/202 preliminary experiments performed with human SHSY 
cells were inconclusive, excellent results were obtained with p-tau ser 396 whose levels 
increased as time of Aβ exposure increased (Figure 15).  Due to problems with the SHSY cells 
such as slow growth and sporadic contamination, we were only able to obtain data for two time 
course experiments, and all subsequent in vitro tau phosphorylation experiments were conducted 
using N2a cells. 
 To test whether hEPN-1 treatment could lower the Aβ-induced increase in p-tau, we 
analyzed the 72 hr time point, which was optimal in the previous experiments.  Although the data 
were somewhat inconsistent, Figure 16 shows an increase in p-tau 199/202 in the presence of 
Aβ, and a decrease in cells also treated with hEPN-1.   One reason the results may have varied is 
that the Aβ and hEPN-1 stock peptides, after being reconstituted, frozen, and thawed several 
times, sometimes lose potency.  To combat this possibility, some experiments were conducted 
with freshly dissolved and/or thawed Aβ or hEPN-1 peptides.  However, even when altering 
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these variables, the results remained inconsistent, so peptide integrity is unlikely the sole factor.   
Adding a greater variety of phosphatase inhibitors to the lysate buffer may help increase Aβ-
induced signals, as might further optimizing the peptide concentrations and treatment times.   
Another variable that could have caused inconsistent results was cell number.  Generally, 
experiments were begun with the same cell numbers, an amount calculated to produce 80% 
confluency in 72 hours.  However, the exact numbers used depended on the growth status of the 
cells.  When cells were strong and growing quickly, fewer cells were initially plated.  Since cell 
density can affect how cells grow and behave, initial variations in cell density between flasks 
could cause changes which could skew expected results.  If too few cells are present there might 
be more Aβ molecules per cell, which results in greater toxicity and any therapeutic agent having 
to work harder to overcome the insult. Conversely, if too many cells are present a protective 
effect occurs and cells overcome the insult regardless of the presence of a therapeutic agent 
(Sundquist et al., 2006).   
 One interesting observation from several of these tau phosphorylation experiments is that 
sometimes, the level of phosphorylated tau in untreated control cells was higher than expected 
(though never higher than in treated cells).  Theoretically, low levels of p-tau are expected in 
control cells since they are not exposed to a phosphorylation-inducing agent (i.e. Aβ).  While 
several sites (serines 199, 202, 235, 262, 396, 404, and threonines 205 and 231) have been shown 
to be specifically hyperphosphorylated in AD, some of these and several other sites are also 
normally phosphorylated in healthy brains for tau to maintain its function (Goedert, 2004).  We 
chose three sites previously thought to be mostly specific to AD, but in our case perhaps our 
tested antibodies to ser 199/202 or ser 396 are not capable of distinguishing normal 
phorphorylation in WT animals from hyperphosphorylation at the same ser sites induced by Aβ.  
66 
In the future, antibodies specific for hyperphosphorylated tau sites should be used once they 
become available, or chemical tests for hyperphosphorylation should be employed.  
The p–tau investigation of mouse brain extracts proved more conclusive.  In Alzheimer’s 
mice treated with vehicle, p-tau Ser 199/202 levels were relatively high, and this signal clearly 
decreased on average in Alzheimer’s mice treated with hEPN-1.  The decrease was not 
significant using the Student’s t-test, however there is a trend that must be further investigated by 
testing more animals.  The p-tau Ser 199/202 signal was unexpectedly variable in WT mice; in 
some individuals it was higher than anticipated, in others it was relatively low (data not shown). 
Thus, although it appears hEPN-1 can lower the p-tau Ser 199/202 signal, it is not clear whether 
this particular site plays a role in AD, in contrast to the literature.  The p-tau Ser 396 site was 
chosen because it is specifically linked to AD (Goedert et al., 1994), but its levels were also 
relatively variable in WT controls (data not shown), which appears to refute the literature.  
Perhaps human and mouse brains phosphorylate tau differently, so this point should be 
investigated further in AD mice.  Thus, while we can speculate that hEPN-1 could be working to 
lower tau phosphorylation in an AD mouse model, more mice must be studied to make an 
accurate conclusion. 
  
TUNEL (Apoptosis) 
A second aspect of AD investigated in this thesis was nuclear DNA fragmentation, a 
hallmark end-stage of cellular apoptosis.  An in vitro model of AD was used to investigate 
apoptosis in the presence of Aβ alone or in conjuction with hEPN-1.  Previous data in our 
laboratory (Kapoor, 2007) showed that caspase-2 and -3 protein levels (and caspase-3 activity) 
increase in SHSY cells exposed to Aβ, so we assumed apoptosis was occurring in our model.  
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However, an increase in caspase protein levels and activation tends to occur early and midway in 
the apoptotic pathway, and it is uncertain whether caspase activation always leads to apoptosis 
(Mondragón-Rodríguz et al., 2008).  Therefore, we tested for nuclear DNA fragmentation that 
generally happens at the end of the pathway, as a more positive indicator that cells have 
undergone apoptosis.  TUNEL staining is a well known method for detecting fragmented DNA. 
Our TUNEL data indicated treatment of cultured cells with Aβ increased the signal 
(further validating our in vitro model), and treatment with Aβ + hEPN-1 prevented this increase 
(Figure 19).  Four variations of the hEPN-1 peptide were tested for efficacy, each synthesized in 
a different proprietary salt to select for the most active drug, and all four drugs successfully 
blocked apoptosis in our model (Figure 20).   Even when hEPN-1 was added 3 or 6 hours after 
Aβ addition, it was still able to significantly lower apoptosis (Figure 22), indicating the drug may 
also work when added post-insult which is more similar to what one would encounter in a 
clinical setting.    To ensure our cell counting method was accurate, one set of data was analyzed 
using a signal threshold method (described in Materials and Methods)(Figure 21).  The trend was 
similar to what was observed in Figure 20, suggesting that our counting method was legitimate.  
In fact, the counting method could perhaps be more accurate because by eye, one can 
discriminate between actual cells versus cell debris, whereas the computer software used in the 
threshold method cannot.  Thus, more false positives might be indentified via the threshold 
method if debris is dark brown. 
 
In Vivo Caspase Studies 
 The final aspect of this thesis focused on an in vivo study of caspase-7, an end-stage 
effector caspase.  Our laboratory previously showed that hEPN-1 mimetics can restore cell 
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survival (Stovall, 2006) and can reduce caspase-2 and -3 protein levels (and caspase-3 activity) 
in vitro (Kapoor, 2007).  We expanded this analysis in vivo using commercially available Alz 
mice, and age matched WT controls (Figure 23).  Brain levels of caspase-7-related protein 
(C7RP) were relatively low in wild type mice, high in Alzheimer’s mice, and low in hEPN-1-
treated Alzheimer’s mice.  Our data show that C7RP levels are significantly higher in vehicle-
treated Alz mice as compared to WT controls.  However, since only 3 animals per treatment 
group were studied, we cannot solely rely on this data.  Since there can be marked variability in 
the health of individual animals, there is likely too much inter-animal inconsistency with only 3 
animals analyzed, so to extend this study more animals should be tested to see if the observed 
trend holds true. 
 
Future Work 
 This thesis has laid the groundwork for several studies that could be conducted in the 
future.  Since this was the first time anyone in our laboratory studied tau phosphorylation, much 
time was spent determining whether the assays worked and optimizing conditions.  However, 
since results were not always consistent, it would be necessary to further optimize experimental 
conditions.  For example, with N2a cells, it would be important to try an Aβ dose-response 
experiment to determine whether their threshold for responding to this insult varies from that for 
SHSY cells.  For all experiments in this thesis, a 20 µM Aβ dose was used, as had worked 
previously in our lab, and that of the peptide’s discoverer (Yankner et al., 1990).  The SHSY 
cells are more fragile, and less hardy than N2a cells, so perhaps a higher Aβ dose might be more 
effective in the N2a’s.  Similarly, testing varying doses of hEPN-1 would also be necessary, 
since our usual 150 µM dose might not be as effective in N2a’s as for SHSY’s.  
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Another aspect to investigate would be different initial plating densities.  Since the 
number of cells in a culture can greatly affect the action of Aβ (too few cells can result in all 
cells being killed, while too many cells can result their overcoming the insult), and this may also 
be the case for hEPN-1, it may be necessary to test several flasks at different starting densities to 
determine which density is ideal for producing results.  Finally, only one antibody to 
phosphorylated tau was tested on the N2a extracts (pTau Ser 199/202), this should be extended 
not only to Ser 396, but also to other known sites with available reagents.   
 Since only preliminary experiments were conducted with SHSY cells for tau 
phosphorylation, further experiments should be performed.  More Aβ time-course studies should 
be done, as well as studies with hEPN-1 treatment, while testing a variety of plating densities, 
and a greater variety of antibodies.   
 With respect to the tau animal studies, we most importantly need to test several more 
animals to achieve more statistically sound results.  This would require either the purchase of 
more animals, or the establishment of a breeding colony here at WPI.  A breeding colony would 
be more cost-effective and theoretically could provide as many mice as required for statistical 
significance.  Antibodies to other tau phosphorylation sites should also be tested to help 
determine sites with low levels of phosphorylation in WT animals, and elevated levels in Alz 
mice, to help determine which sites are important in AD.  Antibodies specific for the 
hyperphosphorylation of tau sites should be used once they become available in the future. Other 
tissues besides brains (from the same mice) could be used as negative controls.  Since tau is 
exclusive to neurons, none should be detected in other tissues of the body.  
 While the data from the TUNEL assay proved the most reliable in this thesis, a great 
amount of time was spent optimizing this assay.  In the future, an SHSY Aβ time-course should 
be performed to determine the optimum time of exposure at a given plating density.  For this 
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thesis, cells were exposed to Aβ for 24 hours; however, longer Aβ exposure might produce even 
better results.  Additionally, trying an Aβ and hEPN-1 dose-response experiments might be 
interesting at various plating densities to determine if 20 µM is in fact a suitable insult or if a 
higher dose produces better results.  For post-insult hEPN-1 addition experiments, it is 
imperative that time points beyond 3 and 6 hours be tested to determine the point at which cells 
can no longer be rescued.  This information is crucial since AD is usually not diagnosed until 
several years after its onset.  In our in vitro accelerated model of AD, cells die within 72 hrs, so it 
is not clear how times of in vitro post-addition will relate to in vivo models.  However, 
uncovering the mechanism of hEPN-1 apoptotic blockage may help, so regardless of its timing in 
vitro or in vivo, markers of this therapeutic pathway could be monitored for effectiveness.   
 In vitro apoptosis studies using the TUNEL assay verified that Aβ truly induces apoptosis 
in this AD model.  hEPN-1 appeared to lower this signal.  Eventually it will be necessary to 
conduct TUNEL assays on brain sections of untreated and hEPN-1 treated Alzheimer’s mice (as 
well as age-matched controls) to analyze apoptosis in specific regions of the brain.  This would 
allow us to determine where neuronal apoptosis is occurring in diseased brains, and also whether 
hEPN-1 is effective at preventing apoptosis in various regions.  A majority of apoptotic cells 
should be viewed in the hippocampus and prefrontal cortex, since those are the major brain areas 
affected in AD, however, it would also be interesting to determine whether apoptotic cells are 
observed elsewhere. 
 Finally, in vivo caspase-7 studies revealed a lowering with hEPN-1 treatment, however, 
as mentioned for the tau hyperphosphorylation studies, more animals must be tested to achieve 
statistical significance.  Additionally, other caspases should be analyzed, including 2, 9, and 12.  
Our previous in vitro findings indicate caspase-2 levels increase in the presence of Aβ, and 
decrease with hEPN-1 treatment (Kapoor, 2007), so this caspase is a good candidate to test in 
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vivo.  Other initiator caspases that could be studied are 8 and 10.  Caspases-9 and -12 would be 
interesting to study since they are both part of the intrinsic pathway.  By studying these caspases, 
we could determine to what extent the intrinsic caspases are expressed, as well as determine if 
hEPN-1 is effective at lowering intrinsic caspase expression. 
The mechanism for how hEPN-1 treatment of cells might be acting to lower apoptosis 
(TUNEL staining), lower caspase-7 protein, and lower tau phosphorylation, is unknown at this 
time.  Our main working hypothesis is that the peptide binds a cell surface receptor that promotes 
a survival pathway and blocks cell death pathways (Kapoor, 2007).  FITC-labeled full length 
ependymin protein, or its mimetics, bind the surface of the cell in a trypsin-dependent and 
saturable manner (unpublished data), suggesting these proteins bind a protein-containing cell 
surface receptor.  Some members of the Bcl-2 family, including Bcl-2 and Bcl-xL, are known to 
be anti-apoptotic and promote cell survival by inhibiting pro-apoptotic members of the Bcl-2 
family (Yuan and Yankner, 2000), so it is possible that these molecules play a role in hEPN-1-
induced survival.  Another way hEPN-1 could promote neuronal survival is by activating cellular 
inhibitors of apoptosis (cIAP’s).  cIAP-1 has been shown to inhibit pro-apoptotic proteins such 
as Smac (second mitochondria-derived activator of caspases), as well as directly inhibit end-
stage caspases-3 and -7 (Van Eden et al., 2004).  cIAP-1 is currently being investigated in our 
lab. 
 In conclusion, the data presented in this thesis demonstrate that: i) Aβ is able to promote 
the phosphorylation of tau in both N2a and SHSY cells, ii) hEPN-1 may lower phosphorylation 
in N2a cells at serines 199/202 and 396, iii) hEPN-1 lowers apoptosis (TUNEL staining) in 
SHSY cells when added both 3 and 6 hours post insult, and iv) hEPN-1 may lower both 
phosphorylated tau and C7RP expression in Alzheimer’s mice. 
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 Alzheimer’s disease is one of the most prevalent and devastating neurodegenerative 
disorders, so it is imperative that sufficient treatments be researched and developed.  Since the 
five FDA-approved drugs on the market only treat symptoms, further effort is required for 
developing a treatment that not only slows disease progression, but also blocks and reverses 
neurodegeneration.  This thesis, as well as previous work in our laboratory, shows that hEPN-1 
targets some aspects of the AD mechanism, and in particular seems to prevent some of the 
neuronal apoptosis which occurs in AD.  Such characteristics could make hEPN-1 neurotrophic 
factor mimetics attractive candidates for AD therapeutics to supplement other approaches being 
investigated for blocking Aβ formation, which could be used to treat some of the 20 million 
sufferers worldwide.  
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